Literature DB >> 32124081

Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients.

Takuya Seike1, Eishiro Mizukoshi2, Kazutoshi Yamada1, Hikari Okada1, Masaaki Kitahara1, Tatsuya Yamashita1, Kuniaki Arai1, Takeshi Terashima1, Noriho Iida1, Kazumi Fushimi1, Taro Yamashita1, Yoshio Sakai1, Masao Honda1, Kenichi Harada3, Shuichi Kaneko1.   

Abstract

BACKGROUND: The interaction between T-cells/fatty acids involved in non-alcoholic fatty liver disease (NAFLD) and liver fibrosis progression is poorly understood. In this study, we conducted a comprehensive analysis of T-cell profiles of NAFLD patients to better understand their relationship with fatty acids and relevance to liver fibrosis.
METHODS: We analyzed the differences in T-cell profiles of peripheral blood mononuclear cells (PBMCs) between 40 NAFLD patients and 5 healthy volunteers (HVs), and their relationship with liver fibrosis stage or progression. Moreover, we analyzed the relationship between T-cell profiles and fatty acid compositions in vivo, and changes in T-cell profiles after treatment with fatty acids in vitro.
RESULTS: T-cell profiles of NAFLD patients were different from those of HVs. The CD25+CD45+CD4+ T-cell frequency was increased in NAFLD patients with high liver fibrosis stage and progression, and this indicated immune activation. Despite such a state of immune activation, the PD1+CD4+ T-cell frequency was decreased in the same patients group. The PD1+CD4+ T-cell frequency had a significantly negative correlation with the serum fatty acid composition ratio C16:1n7/C16:0. Moreover, the PD1+CD4+ T-cell frequency was significantly decreased by in vitro treatment with fatty acids. In addition, its rate of frequency change was significantly different between C16:0 and C16:1n7 and decreased by artificially increasing the C16:1n7/C16:0 ratio.
CONCLUSIONS: The analysis of PBMCs in NAFLD patients showed that T-cell profiles were different from those of HVs. And, it suggested that fatty acids modified T-cell profiles and were involved in liver fibrosis in NAFLD patients.

Entities:  

Keywords:  Fatty acid; Immune cell; Lymphocyte; NAFLD; NASH

Year:  2020        PMID: 32124081     DOI: 10.1007/s00535-020-01679-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  5 in total

Review 1.  The Immunometabolic Roles of Various Fatty Acids in Macrophages and Lymphocytes.

Authors:  Jose Cesar Rosa Neto; Philip C Calder; Rui Curi; Philip Newsholme; Jaswinder K Sethi; Loreana S Silveira
Journal:  Int J Mol Sci       Date:  2021-08-06       Impact factor: 5.923

Review 2.  Diabetic fibrosis.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-12-28       Impact factor: 5.187

Review 3.  Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease.

Authors:  Joeri Lambrecht; Frank Tacke
Journal:  Front Immunol       Date:  2021-02-09       Impact factor: 7.561

4.  Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals.

Authors:  Shihui Li; Eishiro Mizukoshi; Kazunori Kawaguchi; Miyabi Miura; Michiko Nishino; Tetsuro Shimakami; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Masao Honda; Shuichi Kaneko
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

Review 5.  Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment.

Authors:  Ming Yang; Lea Khoukaz; Xiaoqiang Qi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Guangfu Li
Journal:  Biomedicines       Date:  2021-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.